Decibel Therapeutics Inc
DBTX
|
$4.91
-0.81%
-0.2%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (44.8% 1y) (-0.8% 2d) (-1.4% 3d) (0.0% 7d) (283.12% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 123,373,251
https://www.decibeltx.com
Sec Filling | Patents | 40 employees
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all.
urea ceiling treatment gene therapies t-cell
add to watch list Paper trade email alert is off
Press-releases
Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update
Published: 2023-08-11 (Crawled : 12:00) - globenewswire.com
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: -1.16%
H: 1.18%
C: 0.2%
update therapeutics financial results
Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs
Published: 2023-08-09 (Crawled : 12:00) - globenewswire.com
PPRUF | News | $340.0 37.56% 1.5K
|
Consumer Non-Durables
|
| O: 1.36%
H: 3.13%
C: 2.6%
PPRUY | News | $33.79 -0.11% 360K
|
Manufacturing
|
| O: 0.62%
H: 0.32%
C: -0.47%
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: 74.36%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 1.9%
H: 0.0%
C: 0.0%
acquire therapy
Decibel Therapeutics to Participate in the Upcoming Jefferies Healthcare Conference
Published: 2023-06-02 (Crawled : 11:00) - globenewswire.com
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: 2.86%
H: 1.39%
C: -3.01%
conference therapeutics
Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Published: 2023-06-01 (Crawled : 20:00) - globenewswire.com
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: 2.86%
H: 1.39%
C: -3.01%
db-020 meeting trial therapeutics
Decibel Therapeutics to Participate in the Upcoming Barclays 2023 Gene Editing and Gene Therapy Summit
Published: 2023-05-17 (Crawled : 20:00) - globenewswire.com
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: -0.7%
H: 5.67%
C: 5.26%
therapeutics therapy
Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
Published: 2023-05-15 (Crawled : 12:00) - globenewswire.com
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: -3.05%
H: 14.86%
C: 8.0%
update therapeutics financial results
Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO
Published: 2023-05-12 (Crawled : 11:00) - globenewswire.com
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: 0.84%
H: 6.94%
C: 0.28%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.48%
H: 0.36%
C: -0.64%
candidate approval medical application trial therapeutics therapy
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
Published: 2023-05-10 (Crawled : 20:00) - globenewswire.com
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: 0.0%
H: 6.25%
C: 6.25%
cell meeting therapeutics therapy
Decibel Therapeutics Receives European Orphan Drug Designation for Lead Gene Therapy Candidate DB-OTO
Published: 2023-03-30 (Crawled : 17:00) - biospace.com/
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: 12.34%
H: 0.46%
C: -5.88%
drug candidate designation therapeutics therapy
Decibel Therapeutics to Participate in the Upcoming Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days
Published: 2023-03-28 (Crawled : 21:00) - globenewswire.com
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: 0.74%
H: 4.76%
C: -4.03%
rare disease genomic therapeutics
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M
|
Finance
|
22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10